Direkt zum Inhalt
Merck

HMHEMAG-34K

MILLIPLEX® Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay

The Human Metabolic Hormone Panel, using the Luminex xMAP technology, enables the simultaneous analysis of 13 protein biomarkers in human serum, plasma and cell/tissue culture samples.

Synonym(e):

human metabolic hormone immunoassay panel, luminex human metabolic hormone multiplex assay, millipore human metabolism multiplex kit

Anmelden Preise für Organisationen und Verträge anzeigen

Über diesen Artikel

UNSPSC-Code:
12161503
eCl@ss:
32161000

To order a Milliplex® kit, please search for your analyte of interest.

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Speziesreaktivität

human

Hersteller/Markenname

Milliplex®

assay range

accuracy: 101%
(Glucagon)

accuracy: 102%
(Leptin)

accuracy: 103%
(GIP)

accuracy: 103%
(GLP-1 (Total))

accuracy: 105%
(Ghrelin (Active))

accuracy: 106%
(MCP-1)

accuracy: 97%
(TNFα)

accuracy: 99%
(C-Peptide)

sensitivity: 0.5 pg/mL
(MinDC+2SD; TNF?)

sensitivity: 1.1 pg/mL
(MinDC+2SD; GIP)

sensitivity: 13 pg/mL
(MinDC+2SD; IL-6)

sensitivity: 14 pg/mL
(MinDC+2SD; Ghrelin (Active))

sensitivity: 14 pg/mL
(MinDC+2SD; MCP-1)

sensitivity: 146 pg/mL
(MinDC+2SD; PYY)

sensitivity: 15 pg/mL
(MinDC+2SD; Amylin (Total))

sensitivity: 16 pg/mL
(MinDC+2SD; C-Peptide)

sensitivity: 16 pg/mL
(MinDC+2SD; Glucagon)

sensitivity: 160 pg/mL
(MinDC+2SD; Insulin)

sensitivity: 2.4 pg/mL
(MinDC+2SD; GLP-1 (Active))

sensitivity: 2.9 pg/mL
(MinDC+2SD; PP)

sensitivity: 28 pg/mL
(MinDC+2SD; Amylin (Active))

sensitivity: 64 pg/mL
(MinDC+2SD; Leptin)

sensitivity: 7.3 pg/mL
(MinDC+2SD; GLP-1 (Total))

standard curve range: 0.69-500 pg/mL
(TNFα)

standard curve range: 1.4-1,000 pg/mL
(GIP)

standard curve range: 13.7-10,000 pg/mL
(Amylin (Active))

standard curve range: 13.7-10,000 pg/mL
(Amylin (Total))

standard curve range: 13.7-10,000 pg/mL
(Ghrelin (Active))

standard curve range: 13.7-10,000 pg/mL
(Glucagon)

standard curve range: 13.7-10,000 pg/mL
(IL-6)

standard curve range: 13.7-10,000 pg/mL
(MCP-1)

standard curve range: 13.7-10,000 pg/mL
(PYY)

standard curve range: 137-100,000 pg/mL
(Insulin)

standard curve range: 137-100,000 pg/mL
(Leptin)

standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Active))

standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Total))

standard curve range: 2.7-2,000 pg/mL
(PP)

standard curve range: 27.4-20,000 pg/mL
(C-Peptide)

inter-assay cv: <15%
intra-assay cv: <10%
(C-Peptide)

inter-assay cv: <15%
intra-assay cv: <10%
(GIP)

inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Active))

inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Total))

inter-assay cv: <15%
intra-assay cv: <10%
(Ghrelin (Active))

inter-assay cv: <15%
intra-assay cv: <10%
(Glucagon)

inter-assay cv: <15%
intra-assay cv: <10%
(IL-6)

inter-assay cv: <15%
intra-assay cv: <10%
(Insulin)

inter-assay cv: <15%
intra-assay cv: <10%
(Leptin)

inter-assay cv: <15%
intra-assay cv: <10%
(MCP-1)

inter-assay cv: <15%
intra-assay cv: <10%
(PP)

inter-assay cv: <15%
intra-assay cv: <10%
(PYY)

inter-assay cv: <15%
intra-assay cv: <10%
(TNFα)

inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Active))

inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Total))

Methode(n)

multiplexing: suitable

Nachweisverfahren

fluorometric (Luminex xMAP)

Versandbedingung

wet ice

Allgemeine Beschreibung

Metabolic syndrome is a cluster of conditions, including increased blood pressure, elevated insulin levels, excess body fat around the waist, and abnormal cholesterol levels. Key features of metabolic syndrome include insulin resistance, glucose intolerance, hypertension, dyslipidemia, and central obesity—all of which are risk factors for atherosclerosis, coronary heart disease, type 2 diabetes, kidney disease, and even premature death. Adults with metabolic syndrome present a low-grade inflammation, whose link with obesity may be a production of pro- and anti-inflammatory factors. Consequently, research done in this area covers multi-faceted fields of cytokines, acute phase proteins, diabetes, and obesity related hormones, as well as other cardiovascular disease biomarkers.

The MILLIPLEX® Human Metabolic Hormone Panel is a 15 analyte, 13-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and cell/tissue culture samples: Amylin (Active) or Amylin (Total), C-Peptide, Ghrelin (Active), GIP, GLP-1 (Active) or GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNFα. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Metabolism

Anwendung

  • Analytes: Amylin (Active), Amylin (Total), C-Peptide, Ghrelin (Active), GIP (Total), GLP-1 (Active), GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1 (CCL2), Pancreatic Polypeptide (PP), PYY (Total), TNF-α
  • NOTE: The following analytes cannot be assayed simultaneously: Amylin (Active) & Amylin (Total); GLP-1 (Active) & GLP-1 (Total).
  • Recommended Sample Type: Human serum, plasma, and cell/tissue culture supernatants or lysates
  • Recommended Sample Dilution: 25 μL per well of undiluted serum or plasma; cell/tissue culture samples may be used undiluted or diluted with an appropriate control medium NOTE: The following analytes require the addition of protease inhibitors to serum or plasma samples (see sample collection and storage section in the protocol for details): GLP-1 (DPPIV inhibitor); Amylin (protease inhibitor cocktail); Glucagon (Aprotinin); Ghrelin (Active) (serine protease inhibitor).
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Metabolism
  • Research Subcategory: Metabolic Disorders

Leistungsmerkmale und Vorteile

Design your multiplex kit by choosing available analytes within this panel.

Sonstige Hinweise

Please contact Technical Service for linearity of dilution.
Please note: Amylin (Active) and Amylin (Total) cannot be plexed together. GLP-1 (Active) and GLP-1 (Total) cannot be plexed together.
Replaces: HMHMAG-34K

Rechtliche Hinweise

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Piktogramme

Skull and crossbonesEnvironment

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Marta Klementova et al.
Nutrients, 11(1) (2019-01-16)
Gastrointestinal hormones are involved in regulation of glucose metabolism and satiety. We tested the acute effect of meal composition on these hormones in three population groups. A randomized crossover design was used to examine the effects of two energy- and
Brandon G Fico et al.
International journal of exercise science, 13(2), 1819-1825 (2021-01-09)
Swimming is a favorable and ideal modality of exercise for individuals with obesity and arthritis as it encompasses a minimal weight-bearing stress and a reduced heat load. However, the available evidence indicates that regular swimming may not be effective in
Lijuan Sun et al.
The British journal of nutrition, 116(7), 1216-1221 (2016-09-10)
Apart from the well-known action of insulin, the mechanism by which soya and cows' milk improve postprandial glycaemia control was examined. In total, twelve healthy, young, Chinese men were studied on three separate occasions, in random order with isovolumetric (322
Mary R Lee et al.
Neuropharmacology, 170, 107788-107788 (2019-09-27)
Both animal and human work suggests that the ghrelin system may be involved in the mechanisms that regulate the development and maintenance of alcohol use disorder. Previously, in a Phase 1b study, we tested pharmacological blockade of the growth hormone
Nathan C Winn et al.
Medicine and science in sports and exercise, 51(5), 995-1005 (2019-01-30)
Physical inactivity is associated with disruptions in glucose metabolism and energy balance, whereas energy restriction may blunt these adverse manifestations. During hypocaloric feeding, higher-protein intake maintains lean mass which is an important component of metabolic health. This study determined whether

Questions

1–2 of 2 Questions  
  1. How much protease inhibitor should be added when using only the plasma instead of the entire blood sample?

    1 answer
    1. For most protease inhibitors, such as leupeptin and aprotinin, doubling the concentration typically does not negatively impact the assay. However, with specific inhibitors like the DPPIV inhibitor referenced, higher concentrations can interfere with the assay, which is why additional instructions are provided. Other DPPIV inhibitors, such as Diprotin A, do not interfere at any concentration but are not as effective.

      Helpful?

  2. Could you please provide information on the epitopes targeted by the antibodies HMHE-1034-2 and HMHE-1034-1, which are used in the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay? Specifically, I would like to know if the anti-GLP-1 antibody would be able to bind to a commercial drug such as semaglutide.

    1 answer
    1. This antidiabetic medication for the treatment of type 2 diabetes and as anti-obesity medication for long-term weight management is known as Semaglutide. It is sold under the brand names Ozempic, Wegovy, and Rybelsus. Semaglutide was developed by Novo Nordisk in 2012. It is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

      Helpful?

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung